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Abstract
HIV-1 is a retrovirus that integrates into host chromatin and can remain transcriptionally quiescent 
in a pool of immune cells. This characteristic enables HIV-1 to evade both host immune responses 
and antiretroviral drugs, leading to persistent infection. Upon reactivation of proviral gene 
expression, HIV-1 envelope (HIV-1 Env) glycoproteins are expressed on the cell surface, 
transforming latently infected cells into targets for HIV-1 Env-specific monoclonal antibodies 
(mAbs), which can engage immune effector cells to kill productively infected CD4+ T cells and 
thus limit the spread of progeny virus. Recent innovations in antibody engineering have resulted in 
novel immunotherapeutics such as bispecific dual-affinity re-targeting (DART) molecules and 
other bi- and trispecific antibody designs that can recognize HIV-1 Env and recruit cytotoxic 
effector cells to kill CD4+ T cells latently infected with HIV‑1. Here, we review these 
immunotherapies, which are designed with the goal of curing HIV-1 infection.
Efforts to develop new strategies to eradicate the latent pool of HIV-1-infected CD4+ T cells 
were ignited by the unexpected cure of the ‘Berlin patient’ by a bone marrow transplant1. In 
the setting of bone marrow ablation for leukaemia, the patient received bone marrow from a 
donor with a deletion in the HIV-1 receptor CC-chemokine receptor 5 (CCR5Δ32), which is 
resistant to CCR5-tropic HIV-1 (R5 HIV-1)1. Further interest in the possibility of a HIV-1 
cure was stimulated by the case of the ‘Mississippi baby’, who received combination 
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antiretroviral therapy (cART) immediately after birth2. Although the virus 
ultimately rebounded in this baby3, the initial cART prevented the reappearance of viraemia 
for more than a year2 and these clinical observations stimulated new efforts to develop novel 
strategies to cure AIDS.
During acute HIV-1 infection, CD8+ T cell immune responses are generated to eliminate 
virus-infected cells, leading to the partial control of virus replication that contributes to the 
virus set point4 (FIG. 1a). However, full control of virus replication is usually not 
achieved, even in individuals classified as elite controllers. Ultrasensitive assays that 
can detect plasma viraemia at levels below 50 copies per ml have demonstrated that the 
majority of individuals previously defined as elite controllers have blips of detectable 
viraemia of >1 copy per ml over time5,6. Nonetheless, elite controllers can limit the size of 
the latent pool; these individuals have 1.5 log lower median of infectious units per million 
(IUPM) cells compared with chronic HIV-1 progressors who do not naturally control virus 
replication7.
In addition to the cellular immune responses elicited by natural infection, antibody responses 
contribute to the landscape of virus evolution within the infected individuals. Notably, 
neutralizing antibody responses exert immune pressure following acute HIV-1 
infection8–10 and select for immune variants of the HIV-1 envelope (HIV-1 Env) that in turn 
promote the development of broadly autologous neutralizing antibodies11. This co-evolution 
has also been demonstrated during chronic infection12. These autologous neutralizing 
responses were associated with control of virus replication in a subset of infected individuals 
after treatment interruption13. Meanwhile, infusion of the CD20-specific monoclonal 
antibody (mAb) rituximab resulted in loss of control of virus replication14. This effect 
occurred because rituximab depleted B cells and consequently led to the loss of autologous 
neutralizing responses14. Together, these studies provide a rationale for identifying natural 
antiviral mechanisms that can be enhanced and leveraged to eliminate latently infected 
CD4+ T cells and thus cure HIV-1 infection15–17.
The implementation of cART can arrest the clinical progression of HIV-1 infection, increase 
life expectancy and improve the quality of life of HIV-1-infected individuals. However, 
HIV-1 still persists as a transcriptionally quiescent provirus even when cART has been 
administered for more than 10 years18–21 (FIG. 1a). A model of the decay of the pool of 
latently infected CD4+ T cells estimated that it would require at least 73 years of continual 
cART to ablate this reservoir20,22. Despite the inability of cART to eliminate the latent 
reservoir, immediate initiation of cART during the acute phase of infection can reduce the 
size of the reservoir. Indeed, a study using a quantitative viral outgrowth assay 
(QVOA) demonstrated this effect; the early initiation of cART reduced the frequency of cells 
harbouring replication- competent virus23.
Thus, these data indicate that immune responses and cART can constrain the pool of latently 
infected CD4+ T cells, but eradication of the latent T cell pool will require novel immune 
intervention strategies. In this regard, substantial progress has recently been made. HIV-1-
specific mAbs and engineered immunotherapeutics that are based on mAb specificities and 
cellular immune mechanisms have been developed to target the pool of latently infected 
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CD4+ T cells. Here, we discuss how innovative engineered bispecific and trispecific 
antibodies can be utilized in the context of experimental HIV-1 treatment and cure strategies. 
In particular, we focus on the novel mAb-based dual-affinity re-targeting (DART) proteins.
Establishment of latent infection
HIV-1 integration during the infective cycle
The acute phase of HIV-1 infection is characterized by rapid replication of the virus within 
CD4+ T cell subsets and a profound depletion of CD4+ T cells, predominantly in secondary 
lymphoid organs in the gastrointestinal tract24. In particular, HIV-1-specific CD4+ T cells 
are targeted by the virus while the T cells acquire antigen specificity during the transition 
from naive to effector and memory T cells25,26. Acute infection triggers a high level of 
activation of the immune system, including the release of pro-inflammatory cytokines27. 
Thus, the overall T cell compartment is also affected by bystander activation, resulting in 
infection of both naive and memory cells26. HIV-1 can therefore integrate into the genome 
of a broad population of activated proliferating CD4+ T cells. Interestingly, CD4+ T 
follicular helper (TFH) cells are considered the main source of cells that support 
active virus replication in viraemic and treated aviraemic patients during chronic HIV-1 
infection28,29. These findings suggest that TFH cells might, therefore, become part of the 
pool of latently infected cells in the lymph nodes. Both the development of anti-HIV-1 host 
immune responses30–32 and initiation of cART can provide partial control of virus 
replication while immune system activation declines33–35. Notably, CD8+ T cell responses 
may be prevented from reaching infected TFH target cells within lymph node B cell 
follicles36. After cART initiation, some activated cells enter the resting phase of the memory 
response while harbouring integrated and transcriptionally silent provirus. It is this 
population of resting cells that has been defined as the latent HIV-1 reservoir18 (FIG. 1b).
The frequency of latently infected CD4+ T cells was initially estimated to be approximately 
0.05% (500 per 1 × 106) of resting CD4+ T cells, with similar frequencies in lymph nodes 
and blood19. In patients on antiretroviral therapy for more than 30 months, it was estimated 
that 0.2–16.2 per 1 × 106 resting CD4+ T cells could harbour provirus20. This absolute 
frequency of latent HIV-1 infection as measured by QVOA has now been shown to be only a 
minimal estimate. Ho and collaborators determined that <1% of integrated proviruses could 
be induced to release infectious progeny upon maximal in vitro stimulation37. Moreover, 
only a subset (~12%) of the non-inducible provirus-containing CD4+ T cells had intact 
HIV-1 genomes and normal long terminal repeat function37. However, there are 
discrepancies among the different assays used to measure the size of the reservoir, which is 
attributed to the presence of CD4+ T cells harbouring non-integrated replication-competent 
virus38. Additional studies are needed to determine the most sensitive methods to quantify 
the latent reservoir to accurately determine the success of HIV-1 cure strategies39.
Infected cellular subsets that become the reservoir of latently infected CD4+ T cells
Subsets of CD4+ cells are the natural targets of HIV-1. Resting CD4+ T cells that harbour the 
provirus primarily express the memory cell subset marker CD45RO19. This finding indicates 
that memory cells are the principal component of the pool of latently infected cells. Further 
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analyses revealed that both central and transitional memory CD4+ T cells constitute 
reservoirs of persistent HIV-1 (REF. 40). Measurements of integrated HIV-1 DNA in CD4+ 
T cells have demonstrated that the reservoir is represented by 93.8% memory cells and 6.2% 
naive cells in the lymph nodes and by 70.1% memory cells and 20.1% naive cells in the 
periphery25. QVOA analysis of replication-competent virus identified resting central 
memory CD4+ T cells as a stable subset of latently infected cells compared with transitional 
memory cells, which may not represent a persistent reservoir41 because of their shorter 
lifespan. The frequency of central memory CD4+ T cells harbouring replication-competent 
virus ranged from 0.03 to 9.74 IUPM in a cohort of cART-treated acutely and chronically 
HIV-1-infected individuals41. Interestingly, these results supported previous estimates that 
the frequency of latently infected memory CD4+ T cells is <1 IUPM19,42.
Other cell populations in the immune system in addition to the resting CD4+ T memory cell 
subsets may contribute to the pool of latently infected cells. Resting naive CD4+ T cells have 
been identified as potential contributors to the latent HIV-1 reservoir43,44, although it 
remains unclear how persistent viral latency is within this T cell reservoir. 
Macrophages can be infected by HIV-1 and have been identified as carriers of the virus in 
the CNS of patients45. Macrophages are also the main source of HIV-1 production in rhesus 
macaques infected with simian/HIV (SHIV) chimeric virus during a period of profound 
CD4+ T cell depletion46. The persistence of true viral latency within the macrophage 
population has not yet been delineated. It is possible that tissue-resident monocyte-derived 
cells can represent a component of the pool of latently infected cells. Meanwhile, pluripotent 
haematopoietic cells are susceptible to HIV-1 infection via CXC-chemokine receptor 4 
(CXCR4)47, and in vitro experiments have shown that these cells can become latently 
infected48,49. However, the contribution of pluripotent CD34+ cells to the pool of latently 
infected cells has been challenged by Durand and collaborators, who could not detect 
integrated HIV-1 DNA in highly purified cell preparations50. Therefore, the persistence of 
viral latency in cellular subsets other than CD4+ T cells and their contribution to the total 
latent reservoir in vivo currently remains unknown51.
Maintenance of latently infected CD4+ T cells
One explanation for the establishment of the pool of latently infected cells is that a portion 
of CD4+ T cells survives the cytopathic effect of virus replication following acute infection. 
This portion of CD4+ T cells returns to a resting stage, resulting in latency. To maintain 
proviral latency, several molecular mechanisms restrict proviral expression. Epigenetic 
silencing mechanisms, including restrictions associated with deacetylated histones and 
methylated histones, are key regulators of proviral repression. In addition, the following 
non-epigenetic factors influence viral quiescence: the regulation of HIV-1 transcription and 
elongation by Tat; transcriptional interference; the sequestration of transcription initiation 
factors; the regulation of positive transcription elongation factor b (p-TEFb); and the 
restriction of HIV RNA transport52–54.
The proviral integration site can also affect the ability of HIV-1 to start a new replication 
phase upon subsequent activation of the cellular subsets of interest55. Although HIV-1 does 
not specifically target a unique integration site within the human genome, proviral 
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integration sites are disproportionally found in genes related to T cell homeostasis, such as 
BTB domain and CNC homologue 2 (BACH2), and cell growth, such as MKL1/myocardin 
like 2 (MKL2)43,56,57. In addition, HIV-1 integration sites have been identified in proximity 
to the Alu sequences, suggesting that HIV-1 may not necessarily target genes that are 
transcriptionally active at the time of infection48.
In summary, there are two potential mechanisms by which the pool of latently infected 
CD4+ T cells is maintained. The first hypothesis is that the reservoir is maintained through 
the proliferation of clonally expanded CD4+ T cells58. The second hypothesis is that only 
10% of cells in the latent reservoir harbour a single integration site and this population 
declines with a longer half-life during cART. Therefore, the cells with a single integration 
site might be those responsible for the majority of the rebounding of the latent reservoir48. 
Thus, determination of HIV-1 integration sites may lead to new strategies for the reversal 
and clearance of HIV latency during cART.
Immune responses to eliminate latency
The limited ability of the immune system to recognize HIV-1-infected cells following 
reactivation from latency represents a hurdle in the elimination of the latent HIV-1 
reservoir59. The following factors are thought to contribute to this hurdle: the low level of 
HIV-1-specific circulating CD8+ T cells in patients on cART59; the inability of reactivated 
cells to deliver sufficient activation stimuli for the human leukocyte antigen (HLA) class I-
restricted antigen-specific effector cells53,59,60; the inadequate level of expression of HIV-1 
antigens by the reactivated cells51; and the localization of reactivated cells in protected 
sanctuary sites such as lymph node B cell follicles29,36. Moreover, proviral sequences in 
individuals who started cART during the chronic phase of infection carry cytotoxic T 
lymphocyte escape mutations that may reduce CD8+ T cell-mediated elimination of latently 
infected cells61.
Viral diversity and clearance strategies
The immune responses elicited during the acute phase of infection are responsible for 
exerting immune pressure on HIV-1 and inducing the evolution of virus sequences within 
each infected individual. This effect has been demonstrated to be an outcome of both 
cellular31,62–66 and humoral responses8–10,12,67,68, and the immune system struggles to 
adapt to the virus evolution to confer protection from disease progression. Analyses of 
sequences of integrated virus in circulating activated and resting CD4+ T cells from HIV-1-
infected patients on cART indicated that the provirus was represented by a single 
intermixing genetic population69. In another study, when the sequence of the provirus from 
circulating resting CD4+ T cells was compared with that of plasma virus, the results 
indicated that plasma virus was genetically distinct from integrated provirus69. Although this 
finding has not been universally seen in all patients70 and may be due to undersampling, it 
has raised the possibility of a source of residual virus that is distinct from the resting CD4+ T 
cell population. Under this premise, the early initiation of cART could limit the diversity of 
proviral sequences, limit escape mutations and improve the ability of the immune system to 
clear infected cells. A recent analysis of virus sequences obtained at 0, 3 and 6 months post-
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initiation of cART in three patients demonstrated that virus replication persists when the 
plasma virus load is <48 copies per ml71. This persistent virus replication may contribute to 
changes in the sequence diversity of the provirus in the cellular reservoir71. However, these 
findings are in contrast to previous observations that indicated a lack of virus evolution in 
the periphery72,73 and in gut-associated lymphoid tissues73 in individuals on cART74. 
Nevertheless, the possibility of virus replication persisting below detectable levels and 
fostering persistent genetic instability of the reservoir (FIG. 1b) represents substantial 
challenges. That is, it would be particularly challenging for the immune system to adjust to 
sequence evolution even if it seems that the patient is successfully treated with cART. These 
data highlight the need for antiretroviral drug regimens that are able to reach sanctuary sites 
of virus replication and at effective concentrations to inhibit virus replication. More studies 
are needed to confirm these findings.
The reversal of latency in a safe and fully effective manner across the biological and 
anatomical diversity of the HIV reservoir is a daunting task53,60. Initial proposals to reverse 
latency included stimulation of the immune system in patients on suppressive cART through 
the administration of a combination of the CD3-specific mAb OKT3 with anti-CD28 (REF. 
21) or with interleukin-2 (IL-2)75. Data from these initial studies indicated that the co-
administration of OKT3 and IL-2 was toxic and elicited anti-OKT3 antibody responses. 
Moreover, despite strong activation of the immune system, the combination failed to reduce 
the number of latently infected CD4+ T cells.
More recent studies of latency reversing agents (LRAs) have included those that 
inhibit the silencing effects of epigenetic and non-epigenetic restrictions54. These types of 
LRAs induce proviral expression but without overt cellular activation54. Several compounds 
have been identified that can directly or indirectly reverse epigenetic silencing. Compounds 
that can directly reverse epigenetic silencing include inhibitors of histone deacetylase 
(HDAC), histone methyltransferase (HMT) and DNA methylase (DNMT), and have been 
studied in vitro, ex vivo or in clinical trials76. Clinical studies of HDAC inhibitors have 
suggested that even a single dose of the HDAC inhibitor vorinostat could disrupt latency77 
(FIG. 1a,b). This study opened the door to more targeted approaches to reverse latency in the 
absence of high-level immune activation in the hope of achieving clearance of latently 
infected cellular reservoirs. Although several studies have demonstrated the ability of HDAC 
inhibitors to reverse latency, at least transiently78–82, none has demonstrated that induction 
of proviral expression results in the depletion of the pool of latently infected cells. Optimal 
dosing of LRA regimens may need further refinement because a dampened therapeutic 
response has been observed in the patients treated with daily doses of vorinostat83. In an 
encouraging study by Archin and collaborators84, a HMT inhibitor led to a reduction in the 
trimethylation of histone 3 at lysine 27 (H3K27) of the HIV provirus; this result has spurred 
the development of LRAs that could act on other epigenetic restrictions. The possibility of 
combining more than one LRA is now being explored78,80.
Overcoming limitations of immune responses
Novel strategies are needed to achieve HIV-1 cure because neither host immune 
responses59,61 nor a combination of LRA plus cART60,71,85 are effective in reducing the size 
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of the pool of latently infected cells. In addition to the mechanism of virus escape31,63, the 
limited efficiency of CD8+ T cell responses is partially attributed to the exhaustion of these 
cells. This finding has been demonstrated by the expression of cellular exhaustion markers 
such as programmed cell death protein 1 (PD1)86–88. Initiation of cART after infection is not 
capable of fully reverting the exhausted functional phenotype of CD8+ T cells89, which 
could represent a limitation of HLA class I-restricted antigen-specific cells to kill latently 
infected cells. mAbs and mAb-based therapeutics capable of mediating antibody-dependent 
cellular cytotoxicity (ADCC) by recruiting crystallizable fragment (Fc)-gamma receptor 
(FcγR) IIIa-bearing cells, such as natural killer cells, are of particular interest17. In addition, 
the utilization of mAb-based proteins that can recognize infected cells and redirect cytotoxic 
effector T cells independently of HLA class I restriction and exhaustion level to kill infected 
cells has become a strategy for developing new immunotherapies.
HIV-1 Env mAb specificities
A wide repertoire of HIV-1 Env-specific mAbs can mediate ADCC independently of their 
neutralizing functions90. This ability is due to the recognition by mAbs of conformational 
states of the HIV-1 Env glycoproteins expressed on virus-infected cell membranes that may 
be different from those present on virions91,92 (FIG. 2a). The conformational state of the 
functional HIV-1 Env glycoprotein on infectious virions is a ‘closed’ trimeric structure of 
the assembled gp120–gp41 complex. These functional trimers contain numerous epitopes 
that can be targeted by broadly neutralizing antibodies (bNAbs) (FIG. 2b). These epitopes 
include the CD4-binding site (CD4bs), variable regions 1 and 2 (V1V2), glycans at the base 
of variable region 3 (V3), the gp120-gp41 interface, and the membrane external proximal 
region (MPER) (FIG. 2b). VRC01 (REF. 93), VRC07 (REF. 94), b12 (REF. 95) and 
3BNC117 (REF. 96) are bNAbs that target CD4bs, whereas PG9 and PG16 (REF. 97) target 
V1V2. The bNAbs 10–1074 (REF. 98) and PGT121 (REF. 99) target glycans at the base of 
V3, whereas PGT151 targets the gp120-gp41 interface100. Finally, the bNAb 10e8 targets 
the MPER101 (FIG. 2b).
Additional epitopes on the virion can be exposed upon engagement of the cellular CD4 
receptor102 or as a result of the HIV-1 Env adopting different conformational states, 
commonly referred to as ‘breathing motions’ of the viral envelope proteins103–105. This 
change in conformation leads to a more open envelope arrangement that exposes CD4-
inducible epitopes102 in the C1/C2 region of gp120 as well as the HR1-HR2 region of gp41. 
These regions can be recognized by the HIV-1 Env non-neutralizing mAbs A32 (REFS 
106,107) and 7B2 (REFS 108–110). The A32 mAb targets the conformational CD4-
inducible C1/C2 epitope, the earliest epitope to be exposed during cell–cell infection111–113, 
whereas 7B2 targets the HR1-HR2 region of gp41. A key feature of immunotherapeutic 
mAb specificities is their high- affinity recognition of conserved HIV-1 Env structures on the 
surface of infected cells. Maximizing the sensitivity for binding to low levels of cell surface 
envelope glycoproteins upon exposure to an LRA, as well as the kinetics of epitope exposure 
and recognition, is critical for the design of curative strategies based on HIV-1 Env-specific 
mAbs. Utilization of mAbs with specificities that can also neutralize virions, in addition to 
targeting HIV-1 Env on infected cells, will be of additional benefit for clearing virions or 
limiting infectious virion spread.
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Antibodies for treating HIV-1 infection
In the one partially efficacious HIV-1 vaccine trial to date, high levels of antibodies that 
mediated ADCC, but were not broadly neutralizing, correlated with decreased risk of HIV-1 
infection114. ADCC has also been associated with delayed onset of overt disease115,116 and 
with control of virus replication117. Emerging data support the notion of harnessing ADCC-
mediating antibodies to attain a HIV cure because such antibodies can be engineered to 
attack and clear latently infected cells upon reactivation of provirus. Two non-neutralizing 
ADCC-mediating mAbs that show promise for targeting the latent reservoir are 7B2 (REF. 
118) and A32 (REFS 102,107). 7B2 and A32 recognize conserved residues of HIV-1 Env in 
the gp41 immunodominant and C1/C2 gp120 regions, respectively107,119. Although passive 
infusion of these two mAbs did not prevent infection, they did limit the number of 
transmitted/founder (T/F) HIV-1 variants that established infection110. Thus, these 
types of antibodies are useful as models to design more potent antibody therapeutics that can 
redirect cytotoxic cells to recognize reactivated latently infected cells.
bNabs administered individually or in combination have been shown to prevent SHIV 
infection in non-human primates120–128. In some studies, the protective effect of the bNAbs 
also correlated with their Fc-mediated effector functions, including the ability to recruit 
FcγR-bearing effector cells129–134. The importance of mAb-mediated recruitment of FcγR-
bearing cells was recently highlighted by Lu and collaborators135. Accelerated clearance of 
infected CD4+ T cells in a mouse model was observed when the mAb (a variant of 
3BNC117, a CD4bs-specific bNAb96) had a functional Fc domain, and was therefore 
capable of mediating ADCC, but not when the mAb was engineered with an inactivated Fc 
domain135.
The diversity of functions exhibited by bNAbs that target both virions and infected cells 
make them candidates for both treatment and cure of HIV-1 infection. Moreover, bNAbs 
have been demonstrated to suppress viraemia in rhesus macaques chronically infected with 
SHIV136–138. In this model, a cocktail of bNAbs137, including the N332 glycan-dependent 
PGT121 (REF. 99), the CD4bs-specific 3BNC117 (REF. 96) and b12 (REF. 95) mAbs, 
reduced the level of plasma viraemia by 3.1 log within 7 days post-infusion. Moreover, the 
mAb combination reduced proviral DNA levels in secondary lymphoid sites in the gut, 
lymph nodes and peripheral blood. Control was maintained for up to 56 days after levels of 
the mAbs dropped below the limit of detection. A second infusion of the PGT121–3BNC117 
combination controlled rebounding virus, although the control was less sustained. 
Evaluation of the neutralization sensitivity of the SHIV-SF162P3 challenge stock suggested 
that the PGT121 mAb was the most effective in reducing proviral DNA in lymph nodes, 
gastrointestinal mucosa and peripheral blood in addition to decreasing viral load. 
Importantly, infusion of the VCR07-PGT121 mAb combination during the acute phase of 
infection in the SHIV-infected non-human primate model has provided evidence of the 
effectiveness of these mAbs. This combination was able to reduce peak viraemia and the 
size of the pool of latently infected cells139 as well as completely control virus replication 
and prevent the establishment of latently infected cells140. These data raise the possibility 
that bNAbs could have a considerable impact on the pool of latently infected cells by 
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reducing the level of provirus DNA in tissue compartments. However, further studies are 
needed to determine whether these reductions in provirus DNA are sustained.
In a recent study16, a combination of bNAbs comprising 3BNC117, 10–1074 (REF. 98) and 
PG16 (REF. 97) was evaluated in humanized mice infected with the HIV-1YU2 isolate. 
Infusion of this bNAb cocktail after infection resulted in decreased viraemia in ~50% of the 
mice, and mice treated with mAbs demonstrated substantially delayed virus rebound 
compared with mice treated with cART. Moreover, a decline in the level of cellular-
associated DNA was observed only in the aviraemic mice treated with the triple mAb 
cocktail. In the same study, a combination of LRAs (vorinostat, an anti-cytotoxic T-
lymphocyte antigen (CTLA) mAb and I-BET151) induced viraemia in the bNAb-treated 
mice that had previously exhibited undetectable levels of plasma virus load after treatment. 
Interestingly, cell-associated viral DNA was not detected in the mice that showed no 
rebound of viraemia, whereas cell-associated viral DNA was detected at an average of 0.09 
copies per T cell in the animals that had rebounding viraemia. The mechanism by which this 
combination of bNAbs was effective in controlling virus replication was probably through 
the interaction of their Fc domains with FcγRs on effector cells. Animals that received 
mAbs that had critical mutations in their Fc regions — which abrogated murine and human 
Fc receptor binding but retained virus neutralization activity — were more likely to have 
virus rebound at day 44 after the last Ab injection (60% versus 5% for wild-type antibodies). 
The results of this study support those of the study of SHIV-infected non-human primates137 
demonstrating that bNAbs can significantly affect both plasma viraemia and the pool of 
latently infected cells. That is, bNAbs exert their effects by recognizing HIV-1 Env on the 
host cell membrane16 and engaging FcγR-bearing cells, as previously shown in humanized 
mice141. Moreover, these results highlight the importance of engaging FcγR-bearing cells 
for optimal virus control.
A clinical trial of the 3BNC117 mAb has recapitulated the finding of controlled plasma 
viraemia142. The longitudinal observation of the patients enrolled in this study revealed a 
surprising effect on host humoral immune responses; bNAb responses developed that were 
not present before the infusion of the 3BNC117 mAb143. In addition to these studies, the 
VRC01 mAb was also tested for its ability to control virus replication in chronically infected 
individuals144. The administration of a single dose of this mAb induced a reduction of up to 
1.8 log10 in plasma viraemia. However, VRC01-resistant virus was observed in two of the 
eight treated patients before treatment and hampered the therapeutic effect of the mAb. 
Similarly, the appearance of increased resistance, which indicates escape, was observed in 
70% of the 13 individuals treated with 3BNC117 during analytical treatment interruption145. 
Therefore, it is possible that bNAb-based immunotherapy may positively alter the natural 
humoral responses and exploit new unexpected outcomes that have to be further evaluated 
for their impact on both control of virus replication and reduction of the latent reservoir. For 
the latter effect, further studies are also needed to understand the impact that Fc-mediated 
functions of bNAbs have on engaging effector cells to clear the latent reservoir.
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Engineered antibodies with multiple specificities
Innovations in antibody therapeutics have led to the generation of antigen-binding variable 
fragments that can be combined into bispecific or trispecific molecules146,147. There are 
generally two major classes of bispecific and trispecific mAbs: those with or without an 
antibody Fc region. Bispecific antibodies (bsAbs) are molecules engineered with two 
antigen-binding variable fragments of immunoglobulins to recognize two separate antigens. 
These molecules can interact with two different antigens whether they are presented on the 
surface of an individual cell or on two distinct cells. In the latter case, the molecules will 
facilitate cellular interactions and provide specific signals for the desired outcome. Several 
different bsAbs have been designed to diagnose and treat several human diseases, including 
infectious diseases and cancer148.
BsAbs and HIV-1 infection
Initially, bsAbs were designed to target free HIV-1 virions or HIV-1-infected cells based on 
gp41-specific antibodies. Studies have demonstrated their ability to mediate virus 
neutralization149, combined neutralization and ADCC150, and redirection of CD3+ T cells 
against HIV-1-infected or latently infected cells lines151. A more recent bispecific approach 
was taken by Sun and collaborators, who designed iMabm36, a bsAb that combines iMab 
(the CD4-specific mAb ibalizumab) with two copies of m36 (a single domain, neutralizing, 
HIV gp120-specific antibody)152. iMabm36 exhibited a higher neutralizing capacity than 
m36 alone; iMabm36 was capable of neutralizing 83% of 118 pseudoviruses with a half-
maximal inhibitory concentration (IC50) value of <0.1 μg per ml. A clinical trial has been 
designed to evaluate the activity of this bsAb for treating HIV-1 infection.
The most recent analyses of the potency and breadth of bNAbs against HIV-1 prompted 
studies aimed at designing an immunoglobulin with an antigen-binding fragment that can 
independently recognize two different HIV-1 Env epitopes while having a common Fc 
region (FIGS 2c,3a). Four independent bsAbs were developed using combinations of bNAbs 
described in the previous section: VRC07 × 10e8, VRC07 × PGT121, VRC07 × PG9-16 and 
10e8 × PG9-16 (REF. 153). The in vitro neutralization profiles of these bsAbs at 25 μg per 
ml revealed that they retained the breadth of both parental bNAbs, neutralizing >94% of the 
pseudoviruses representing 206 HIV-1 isolates. The most promising bispecific combination 
was VRC07 × PG9-16, which neutralized >84% of pseudo viruses with an IC50 of <1 μg per 
ml. Moreover, this bsAb combination neutralized all ten pseudoviruses resistant to VRC07 
or PG9-16 alone. Notably, VRC07 × PG9-16 displayed 3-fold to 37-fold increased potency 
compared with the individual mAbs against 8 out of 10 resistant pseudoviruses included in 
the panel tested. Studies using uninfected non-human primates did not reveal any difference 
in the pharmacokinetics between the parental bNAbs and the bsAbs. This result represents 
an encouraging advance in designing bsAbs that could be used for the treatment and/or cure 
of HIV-1 infection.
Bispecific BiTE and DART molecules
bsAbs have been engineered so that one arm recognizes antigens on the surface of target 
cells while the second arm recognizes functional receptors on the surface of effector cells to 
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mediate target-specific redirected killing activity. The first generation of molecules, termed 
bispecific T cell engagers (BiTEs), consisted of two single-chain variable fragments from 
different antibodies joined by a single polypeptide linker154. One fragment was designed to 
bind CD3+ T cells (CD4+ or CD8+) via the CD3 receptor and the other fragment was 
designed to bind a tumour cell via a tumour-specific antigen. The redirected T cell killing of 
antigen-expressing target cells by bsAbs is concomitant with effector T cell activation, 
proliferation and upregulation of granzyme B and perforin155,156. Moreover, the effects of 
bsAbs are induced in a manner that is independent of major histocompatibility complex I 
(MHC I) or co-stimulatory molecules155,156. These bispecific T cell- redirecting molecules 
are reported to be effective in vivo at doses several-fold lower than those typically required 
for mAbs157. Multiple BiTE molecules have advanced into clinical development for the 
treatment of malignancies148, and blinatumomab (a CD19 × CD3 BiTE) was approved in 
2014 by the US Food and Drug Administration (FDA) for the treatment of acute 
lymphoblastic leukaemia158.
The dual-affinity re-targeting (DART) scaffold is a novel bsAb-based modality that offers 
improved stability, manufacturability and potency compared to the BiTE format159–161. In 
DART molecules, the variable domains of the two antigen-binding moieties are incorporated 
into a disulfide-linked heterodimer. Short linkers between the variable light chain and 
variable heavy chain segments of this heterodimer promote a ‘diabody’-type association, 
with the disulfide bond stabilizing the structure (FIGS 2c,3b).
Moore and collaborators generated and compared side-by-side the in vitro performance of 
CD19 × CD3 BiTE and DART proteins based on the same anti-human CD3 and anti-human 
CD19 sequences as blinatumomab160. The crystal structure of a disulfide-constrained DART 
molecule showed that it assembles into a novel compact structure, with the two antigen-
binding sites separated from each other by approximately 30 Å and facing approximately 
90° apart162. The orientation and short distance between the antigen-binding domains of the 
DART protein may facilitate more efficient synapse formation between the T cell and the 
target cell and contribute to an increase in potency of T cell-directed lysis compared with 
other bsAb formats. Therefore, it was suggested that the more rigid and compact 
conformation of the DART protein compared to the BiTE protein could be responsible for 
the higher potency of DART proteins in redirecting T cell killing activity and inducing T cell 
activation159–161. These data make the case for the evaluation of DART molecules that 
redirect T cells to target and destroy HIV-1-infected cells.
DART molecules targeting HIV-1 Env-expressing cells
As the combination of an LRA with cART is not sufficient to reduce the size of the pool of 
latently infected cells, additional strategies are needed to mediate the clearance of the HIV-1 
Env-expressing infected cells. Sung and colleagues designed DART molecules with HIV-1 
Env and CD3 specificities and evaluated these molecules for their capacity to recruit and 
redirect cytotoxic T effector cells to infected CD4+ cells expressing HIV-1 Env on their 
surface119. The HIV-1-specific arm was based on the A32 and 7B2 non-neutralizing mAbs, 
which target the CD4-inducible C1/C2 and gp41 cluster I antigens, respectively119. The T 
cell-binding arm was based on a mAb that targets the CD3ε component of the T cell 
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receptor complex. In vitro studies of lymphocytes from HIV-1 seronegative individuals 
demonstrated that the A32 × CD3 and 7B2 × CD3 DART proteins were capable of recruiting 
up to 25% of the total resting CD3+CD8+ population at a 50% effective concentration 
(EC50) of <1 and 10 ng per ml, respectively. When lymphocytes from HIV-1 seropositive 
patients were stimulated with an LRA (vorinostat) or a mitogen (phytohaemagglutinin) and 
then incubated with the DART molecules, the virus recovered in supernatants was 
substantially reduced (by 40–100%). A combination of the two DART molecules was 
always as effective as the most potent individual DART molecule in each patient sample. 
This finding suggests that DART molecules do not seem to exhibit antagonistic effects and 
that combinations of DART molecules may be an effective way to increase the breadth of 
activity against diverse HIV-1 isolates in the clinical setting. Interestingly, when 
degranulation of T cells from HIV-1-infected individuals was characterized in vitro, it was 
noted that both CD8+ T cells and uninfected CD4+ T cell were engaged by the CD3 
specificity of the DART molecule and degranulated. These results suggest that CD4+ T cells 
contribute to the cytotoxic effects mediated by the DART molecule. Moreover, CD4+ T cells 
can act as effector cells and support the elimination of latently infected cells even in absence 
of the effector CD8+T cell subsets, although the latter subsets are more proficient in 
promoting cytolysis.
A subsequent study by Sloan et al.163 evaluated HIV × CD3 DART molecules in which the 
HIV-specific arm was based on bNAbs that target the N332-glycan (PGT121)99, V1V2 
(PGT145)164, the CD4 binding site (CD4bs) (VRC01)93 and MPER (10e8)101. Of these 
bNAb-based DART molecules, PG121 × CD3 exhibited the highest potency when tested 
against CD4+ T cells infected with diverse HIV-1 isolates; its potency was comparable to 
that of A32 × CD3 and 7B2 × CD3 (EC50 values: 4.2–5.5 pM for A32 × CD3, 1.9–20.5 pM 
for 7B2 × CD3, and 0.2-24pM for PGT121 × CD3). Paired combinations of these three 
DART molecules revealed that neither antagonistic nor apparent synergistic effects were 
observed for their cytotoxic activity, which was probably due to the high level of potency of 
the individual molecules under the given assay conditions. Notably, when cells from HIV-1-
infected patients were incubated with the protein kinase C agonist indolactam to reactivate 
virus replication, the DART molecules mediated >74% virus reduction in two out of four 
patient samples. It is theoretically possible that the CD3-directed portion of the DART 
molecule may stimulate infected CD4+ T cells and thereby facilitate viral spread. However, 
data from Sung et al.119 and Sloan et al.163 indicated that no increase in virus replication 
occurred when DART molecules were incubated with infected CD4+ cells in the absence of 
CD8+ effector cells. Together, these two studies119,163 demonstrate the in vitro potency of 
HIV × CD3 DART proteins and provide a strong foundation for the testing of these first-
generation DART proteins in clinical trials.
A different HIV × CD3 bispecific molecule, in which the anti-HIV arm was based on a 
bNAb targeting the CD4bs (VRC07)94, was evaluated by Pegu and collaborators165. The 
structure of this bispecific molecule differed from that of DART molecules in that a CD3-
specific single-chain variable fragment arm was linked to the light chain of the antigen-
binding fragment of the VRC07 mAb. This protein was named VRC07-αCD3 (REF. 165). 
Similar to the DART molecules, VRC07-αCD3 did not induce activation of either CD8+ or 
CD4+ T cells in the absence of target cells expressing HIV-1 Env. The investigators 
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determined that VRC07-αCD3 directed the cytotoxic activity of resting CD8+ T cells 
obtained from healthy HIV-1 seronegative donors against several cell lines infected with 
HIV-1. This experiment represented models for constitutive or inducible HIV-1 expression, 
with the latter considered as a model for in vitro latency. Notably, VRC07-αCD3 was also 
tested for its ability to recognize latently infected cells present in peripheral blood 
mononuclear cells obtained from eight HIV-1-infected donors who were on suppressive 
cART. After 2 days of incubation with VRC07-αCD3 in the absence of any other 
stimulation or effector cells, the CD4+ T cells from all donors expressed HIV-1 Env on their 
surface. Most importantly, the frequency of proviral DNA-positive CD4+ T cells was 
decreased in the cultures of five out of eight subjects165.
Future directions
The path forward for identifying superior molecules for HIV-1 cure will require an in-depth 
understanding of how to effectively target infected cells that express low levels of HIV-1 
Env. In addition, the molecules must be able to access difficult-to-reach anatomical sites 
harbouring the latent virus reservoir. Subsequent engineering improvements of these 
molecules are also needed to enhance the capacity to engage the most potent effector cells 
and to achieve a longer in vivo half-life. Preclinical studies conducted in the SHIV-infected 
non-human primate model have indicated that administration of recombinant adeno-
associated virus vectors engineered to express a CD4-immunoglobulin fusion protein in 
combination with a small CCR5-mimetic sulfopeptide appear to be well tolerated166. 
Moreover, this construct was capable of protecting the animals from multiple challenges of 
SHIV-AD8 for up to 40 weeks166. These results provide encouraging initial observations on 
the safety of long-term administration of a mAb-derived molecule. Nevertheless, the safety, 
immunogenicity potential and, ultimately, efficacy of these novel proteins will have to be 
addressed by appropriate clinical studies.
It is clear that peripheral blood and secondary lymphoid organs are not the only sites that 
harbour latently infected cells. Bone marrow or the CNS may also represent a sanctuary 
component of the HIV-1 reservoir167,168 and would need to be effectively targeted by 
immunotherapeutics. Encouraging results from in vitro analyses of DART molecules with 
different HIV-1 Env specificities suggest that they may have additive effects119,163 when 
combined, which may help eliminate the impact of virus mutations. Improved effector 
function by DART molecules may be achieved with an effector cell-binding arm based on a 
CD16-specific (FcγR IIIa) antibody instead of the CD3-specific antibody (FIG. 3b). A 
combination of HIV DART molecules with different effector arms would facilitate the 
engagement of different effector cell populations (for example, natural killer cells and 
cytotoxic T cells) that may differentially migrate to the anatomical sites where infected 
target cells reside. Moreover, there have been promising improvements in the in vivo half-
life160–163. Incorporation of an engineered Fc domain with L234A/L235A amino acid 
substitutions that prevent binding to activating FcγRs but retain neonatal Fc receptor binding 
increased the half-life of the DART molecule while maintaining potent killing of HIV-1-
infected CD4+ T cells163.
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Ongoing studies are also exploring molecules beyond bispecificity to determine whether the 
generation of trispecific or tetraspecific antibody-derived molecules against HIV-1 could 
achieve better antiviral activity, in a similar manner as has been reported for an anticancer 
trispecific antibody146,147.
Along with efforts to improve the current proteins and to design novel proteins capable of 
recognizing infected cells, the field is also exploring proteins that can rescue exhausted 
effector cells. Examples include agents that can interfere with the interaction of PD1 and/or 
CTLA4 with their ligands169–171, and novel antibody-based proteins that incorporate such 
agents.
Finally, even with improvements in these therapeutic agents and enhancements in immune 
targeting, it will be important to find the necessary strategies that can disrupt the sanctuaries 
of virus replication36 that remain inaccessible.
Conclusions
Bispecific and trispecific antibodies with multiple broadly reactive anti-HIV-1 specificities 
have been developed to augment the breadth of recognition and neutralization of diverse 
HIV-1 isolates. In addition, novel bsAb-derived molecules, such as those in BiTE or DART 
formats, have been designed to co-engage HIV-1 Env-expressing target cells with cytotoxic 
effector cells. The aim of BiTE and DART molecules is to enhance the clearance of latently 
infected CD4+ T cells upon HIV-1 provirus reactivation through natural or drug-induced 
means. These novel immunotherapeutics are based on high-affinity HIV-1 Env-specific 
mAbs that may be either neutralizing or non-neutralizing. The key feature is that they must 
be directed against broadly conserved regions of cell surface-expressed virus antigen to 
expand the breadth of recognition of cells infected with diverse HIV-1 isolates10. A major 
advantage of these immunotherapeutic molecules that redirect effector cells to antigen-
expressing targets is that they are highly potent. Moreover, they will engage cytotoxic 
cellular subsets independently of antigen HLA class restriction and T cell receptor clonal 
specificity. In addition to the initial in vitro observations, preclinical studies using 
appropriate animal models will be needed to document safety and to support their clinical 
development for the treatment of HIV-1 infection. Current and planned clinical trials 
utilizing these exciting new reagents will provide important new insights into the 
development of innovative immunotherapeutic regimens for HIV-1 cure.
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Glossary
Combined antiretroviral therapy (cART)
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A HIV treatment regimen that uses a combination of drugs from two different classes of 
antiretrovirals that can act as inhibitors of at least two enzymes essential for the replicative 
cycle of HIV-1. The four major classes of antiretrovirals are nucleotide reverse transcriptase 
inhibitors, non-nucleotide reverse transcriptase inhibitors, protease inhibitors and integrase 
inhibitors
Virus set point
The level of viraemia reported as viral RNA copies per ml of plasma in a person infected 
with HIV. The viraemia level becomes relatively stable after the period of acute HIV 
infection, and usually remains stable until the onset of late-stage AIDS. The set point is 
thought to reflect the balance between the replicative capacity of the virus and partial control 
by the immune system
Elite controllers
Elite controllers are canonically defined as people in whom viraemia is below the limit of 50 
copies per ml of plasma for three consecutive measurements performed over a period of 1 
year while not on antiretroviral therapy. The ability of these individuals to control virus 
replication in the absence of therapeutic intervention is related to unique aspects of their 
humoral and/or cellular immune responses
Neutralizing antibody
An antibody that defends a cell from infectious pathogens or toxins by neutralizing their 
biological effects. In the case of HIV-1, neutralizing antibodies prevent the virus from 
entering target cells expressing the CD4 receptor and the co-receptor CC-chemokine 
receptor 5 (CCR5) or CXC-chemokine receptor 4 (CXCR4)
Quantitative viral outgrowth assay (QVOA)
A standard assay used to estimate the frequency of latently infected cells in an HIV-infected 
individual. The assay requires isolation of resting memory CD4 T cells from the infected 
patient on antiretroviral therapy. The cells are stimulated and co-cultured with allogeneic 
CD4 T cells in multiple wells in a limiting dilution manner for a minimum period of 2 
weeks. The frequency of replication- competent virus, or as infectious units per million 
(IUPM), is assessed by measuring the frequency of cultures expressing HIV-1 p24 antigen in 
the supernatant
CD4+ follicular helper T (TFH) cells
A subset of the CD4 T cell population specialized in providing help to B cells within 
secondary lymphoid tissues. TFH cells are identified according to the cell surface expression 
of several different molecules, including CXC-chemokine receptor 5 (CXCR5), programmed 
cell death protein 1 (PD1), SLAM-associated protein (SAP) and inducible T cell co-
stimulator (ICOS). These cells can also produce interleukin-21 and express the transcription 
factor B cell lymphoma 6 (BCL-6). TFH cells are important for the formation of the germinal 
centre where they regulate the differentiation of B cells into plasma cells and memory B 
cells, thus regulating the antibody responses against pathogens
Viral latency
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The ability to remain dormant within the host cell to establish a persistent occult infection. 
In the case of HIV-1, the viral genome is integrated into the DNA of the host cell as a 
provirus. Latency can be reversed, allowing viral RNA, protein and even virion production 
from the latently infected cell upon viral genome reactivation as a consequence of cellular 
signals. This latent HIV DNA genome can also be expanded during cellular replication in 
the absence of viral gene expression
Escape mutations
Mutations in the virus genome that encode modified gene products that will retain their 
function and preserve replication and assembly of infectious particles, but prevent 
recognition by immune responses directed against the parental gene product
Latency reversing agents (LRAs)
A relatively new class of agents used to selectively activate the provirus by interfering with 
the mechanisms reportedly identified to prevent HIV-1 expression in the latently infected 
cells or by promoting transcription of the provirus. Ideally, these agents should specifically 
stimulate virus reactivation but induce minimal activation of cellular subsets of the immune 
system
Epitopes
Portions of a molecule that are recognized by the immune system as non-self antigens and 
therefore capable of inducing antibody and/or cellular immune responses
Transmitted/founder
The transmitted/founder virus is a molecular definition of the virus whose genomic sequence 
is identified following acute infection as the earliest virus transmitted and is responsible for 
the productive clinical infection
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Figure 1. Dynamics of virus replication and therapeutic interventions
a | The blue line represents a representative estimate of the viraemia (virus load, copies per 
ml of plasma) in a HIV-1-infected patient. Initial HIV-1 replication within the CD4+ T cell 
compartment results in viraemia levels that can reach millions of copies per ml. Natural 
immune responses generally cannot control this level of virus replication. Upon initiation of 
combination antiretroviral therapy (cART), plasma levels of virus decline in three phases 
(indicated by 1, 2 and 3), which is related to the elimination of different subsets of infected 
cells172–175. This decline culminates in residual levels of virus in plasma that are below the 
limit of detection. Nonetheless, latently infected cells persist in patients maintained on cART 
even when virus load is undetectable18–21. Latency reversing agents (LRAs) can be used to 
reactivate the provirus41,77 while cART therapy is maintained according to the ‘shock and 
kill’ strategy77,176. Hypothetically, this strategy could eliminate the pool of latently infected 
cells, but clinical trail data have yet to provide evidence that this could be the final 
outcome60, 76–84. b | This schematic represents the temporal impact that immune responses 
and drug therapy have on the changes in the level of virus load as displayed in part a. The 
diagnosis of HIV-1 infection and initiation of cART usually occurs at a time when immune 
responses are initiated but not yet effective in controlling virus replication as indicated in 
part a. This inefficient immune response results in the development of a pool of latently 
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infected cells and cART cannot prevent their formation or eradicate them. The only 
opportunity for cART to be effective would be at a time when spontaneous virus replication 
takes place. In this scenario, mathematical modelling has proposed that it may take up to 73 
years of cART to eliminate any residual infected cells20,22. The concomitant administration 
of LRAs to reactivate HIV-1, referred as ‘shock’, will still rely on a suboptimal natural 
immune response, responsible for the ‘kill’, to eliminate the latent reservoir of virus, 
whereas the cART will protect uninfected cells from becoming infected. Therefore, it is now 
proposed that HIV-1 envelope-specific monoclonal antibody (mAb)-based strategies, 
including dual-affinity re-targeting (DART) molecules, can be implemented to provide 
additional cytotoxic functions (the kill) to the immune responses by mediating the 
elimination of the latent reservoir during reactivation of the provirus.
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Figure 2. HIV-1 envelope epitopes, monoclonal antibodies and engineered antibody-based 
proteins
a | HIV-1 envelope proteins can be expressed in different conformational structures referred 
to as closed or open trimers, monomers and stumps. b | Each envelope conformation is 
susceptible to recognition by monoclonal antibodies (mAbs) defined as those with 
neutralizing (nAbs) and non-neutralizing (non-nAbs) activity. All mAbs depicted in the 
figure have already been used to treat simian/HIV (SHIV) infection in animal models or 
HIV-1 infection in pilot clinical trials. c | These mAbs have been used to engineer new 
molecules such as bispecific mAbs (top) or dual-affinity re-targeting (DART) proteins 
(bottom) with the goal of improving the recognition of HIV-1 Env on the surface of infected 
cells and to recruit effector cells to mediate their clearance. CD4bs, CD4 binding site; 
MPER, membrane external proximal region; V, variable region; VH, variable heavy chain; 
VL, variable light chain.
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Figure 3. Recruitment of effector cell subsets
a | Monoclonal and bispecific antibodies engineered with the crystallizable fragment (Fc) 
region will engage Fcγ receptor (FcγR)-bearing cells such as natural killer cells, monocytes 
and macrophages, polymorphonucleated cells and γ/δ T cells. b | Dual-affinity re-targeting 
(DART) proteins can be engineered with an effector arm based on CD3-specific or CD16-
specific antibodies that are capable of binding CD3+ T cells or FcγR-bearing cells, 
respectively. Env, envelope; VH, variable heavy chain; VL, variable light chain.
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